Dr Reddy’s Cheminor merger: A pharma wedding finalised - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Jun 1, 2000 - Dr Reddy’s Cheminor merger: A pharma wedding finalised

Dr Reddy’s Cheminor merger: A pharma wedding finalised

Jun 1, 2000

Dr Reddy’s Laboratories (DRL) is to merge its sister concern Cheminor Drugs (Cheminor) with the merger ratio set at 9 shares of DRL for every 25 shares of Cheminor. The merger will make Dr. Reddy’s the third largest pharmaceutical player in India, with a post- integration turnover of above Rs. 8 billion in FY 2000. The management aims at a turnover of over Rs 10 bn in FY 2001 which it should it able to achieve if the growth in its main brands viz. Omez (anti–ulcer), Nise (anti–pain), Stamlo (cardivascular) and Ciprolet (anti–infective) in FY2000 are any indication. These brands contributed over 40% of the company’s turnover and will continue to be a major driver for the merged company’s topline.

Another driver of the topline would be the generics business in the regulated markets, which was being undertaken via Cheminor. (Cheminor recently entered the global generics markets with the export of Ranitidine-75Mg and Flouxetine to North America.)

The third driver of the integrated company’s turnover would be the revenues from any Novel Drug Discovery (NDDS). At present, DRL itself is working on three new molecules. One is an anti–cancer compound, another was a Cox II inhibitor (anti–pain) and third was a compound indicated for metabolic disorders. The company foresees licensing out two of these to MNCs for clinical trials in the near future. Besides, the company is also working on a new class of diabetes products called PPAR, expected to have considerable potential.

The main promoter of the group companies, Dr. Reddy’s Holdings (DRH), currently holds 25.40% in DRL and 35.34 % in Cheminor. The holding of DRH in the merged entity will be 27.59%. In their individual capacities, Dr. Anji Reddy and his immediate family members hold 1.76% in DRL and 13.42% in CDL. In the merged entity their combined holding will be 3.86%.

The merger ratio too seems to be slightly weighted in favour of the Cheminor considering the fact that its turnover was Rs 2154 m in FY 2000 i.e. around 36% of the DRL’s turnover. (DRL’s turnover inclusive of American Remedies’ numbers amounted to Rs 5870 m in FY2000.) Moreover growth in the domestic bulk actives market has actually been negative. However weightage seems to have been given to the fact that 67% of Cheminor’s turnover is accounted for by exports and the company has already filed six abbreviated new drug applications (ANDAs) in the US, four in the European Union apart from another six, which are in the pipeline.

Equitymaster requests your view! Post a comment on "Dr Reddy’s Cheminor merger: A pharma wedding finalised". Click here!

  

More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO (Views On News)

Jun 15, 2021

All you need to know about the IPO of Krishna Institute of Medical Sciences.

Why Did Shares of Divi's Lab Rally Today? (Views On News)

Jun 10, 2021

The stock jumped 3.6% in intraday trade to hit its 52-week high.

Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

Jun 8, 2021

Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors (Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

My 'Unlock' Investments (Fast Profits Daily)

Jun 11, 2021

The best unlock investments you can make in the market.

The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

How I Discovered a 400-Year-Old Open Secret to Extreme Wealth (Profit Hunter)

Jun 11, 2021

Charlie Munger's open secret about investing success.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 18, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - ACTAVIS COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS